1.
Murphy GS, Szokol JW, Marymont JH, Greenberg SB, Avram MJ, Vender JS. Residual neuromuscular
blockade and critical respiratory events in the postanesthesia care unit. Anesth Analg. 2008;107:130–7.
2.
Brull SJ, Naguib M, Miller RD. Residual neuromuscular block: rediscovering the obvious.
Anesth Analg. 2008;107:11–4.
3.
Donati F. Residual paralysis: a real problem or did we invent a new disease? Can J
Anaesth. 2013;60:714–29.
4.
Naguib M, Kopman AF, Lien CA, Hunter JM, Lopez A, Brull SJ. A survey of current management
of neuromuscular block in the United States and Europe. Anesth Analg. 2010;111:110–9.
5.
Naguib M, Brull SJ, Kopman AF, et al. Consensus statement on perioperative use of
neuromuscular monitoring. Anesth Analg. 2018;127:71–80.
6.
Cammu G, De Witte J, De Veylder J, Byttebier G, Vandeput D, Foubert L, et al. Postoperative
residual paralysis in outpatients versus inpatients. Anesth Analg. 2006;102:426–9.
7.
Nemes R, Fülesdi B, Pongrácz A, Asztalos L, Szabó-Maák Z, Lengyel S, et al. Impact
of reversal strategies on the incidence of postoperative residual paralysis after
rocuronium relaxation without neuromuscular monitoring: a partially randomised placebo
controlled trial. Eur J Anaesthesiol. 2017;34:609–16.
8.
Beemer GH, Rozental P. Postoperative neuromuscular function. Anaesth Intensive Care.
1986;14:41–5.
9.
Della Rocca G, Pompei L, Pagan DE Paganis C, Tesoro S, Mendola C, Boninsegni P, et
al. Reversal of rocuronium induced neuromuscular block with sugammadex or neostigmine:
a large observational study. Acta AnaesthesiolScand. 2013;57:1138–45.
10.
Brueckmann B, Sasaki N, Grobara P, Li MK, Woo T, de Bie J, et al. Effects of sugammadex
on incidence of postoperative residual neuromuscular blockade: a randomized, controlled
study. Br J Anaesth. 2015;115:743–51.
11.
Kotake Y, Ochiai R, Suzuki T, Ogawa S, Takagi S, Ozaki M, et al. Reversal with sugammadex
in the absence of monitoring did not preclude residual neuromuscular block. Anesth Analg. 2013;117:345–51.
12.
Norman G, Monteiro S, Salama S. Sample size calculations: should the emperor's clothes
be off the peg or made to measure? BMJ. 2012;345:e5278.
13.
Debaene B, Plaud B, Dilly MP, Donati F. Residual paralysis in the PACU after a single
intubating dose of nondepolarizing muscle relaxant with an intermediate duration of
action. Anesthesiology. 2003;98:1042–8.
14.
Esteves S, Martins M, Barros F, Barros F, Canas M, Vitor P, et al. Incidence of postoperative
residual neuromuscular blockade in the postanaesthesia care unit: an observational
multicentre study in Portugal. Eur J Anaesthesiol. 2013;30:243–9.
15.
Yip PC, Hannam JA, Cameron AJ, Campbell D. Incidence of residual neuromuscular blockade
in a post-anaesthetic care unit. Anaesth Intensive Care. 2010;38:91–5.
16.
Butterly A, Bittner EA, George E, Sandberg WS, Eikermann M, Schmidt U. Postoperative
residual curarization from intermediate-acting neuromuscular blocking agents delays
recovery room discharge. Br J Anaesth. 2010;105:304–9.
17.
Baillard C, Clec'h C, Catineau J, Salhi F, Gehan G, Cupa M, et al. Postoperative residual
neuromuscular block: a survey of management. Br J Anaesth. 2005;95:622–6.
18. Murphy GS, Szokol JW, Avram MJ, Greenberg SB, Marymont JH, Vender JS, et al.
Intraoperative acceleromyography monitoring reduces symptoms of muscle weakness and
improves quality of recovery in the early postoperative period. Anesthesiology. 2011;115:946–54.
19. Stouffs A, Ibsen A, Jamart J, Dubois V, Dubois PE. Philips Intellivue NMT
module: variability of initial measurements. J Clin Monit Comput. 2018;32:965–6.
20.
Todd MM, Hindman BJ. The implementation of quantitative electromyographic neuromuscular
monitoring in an academic anesthesia department: follow-up observations. Anesth Analg. 2015;121:836–8.
21. Fuchs-Buder T, Nemes R, Schmartz D. Residual neuromuscular blockade: management
and impact on postoperative pulmonary outcome. Curr Opin Anaesthesiol. 2016;29:662–7.
22. Thilen SR, Ng IC, Cain KC, Treggiari MM, Bhananker SM. Management of rocuronium
neuromuscular block using a protocol for qualitative monitoring and reversal with
neostigmine. Br J Anaesth. 2018;121:367–77.
23. Murphy GS, Kopman AF. Neostigmine as an antagonist of residual block: best
practices do not guarantee predictable results. Br J Anaesth. 2018;121:335–7.
24.
Murphy GS, Szokol JW, Marymont JH, Franklin M, Avram MJ, Vender JS. Residual paralysis
at the time of tracheal extubation. Anesth Analg. 2005;100:1840–5.
25.
Thilen SR, Hansen BE, Ramaiah R, Kent CD, Treggiari MM, Bhananker SM. Intraoperative
neuromuscular monitoring site and residual paralysis. Anesthesiology. 2012;117:964–72.
26. Baillard C, Bourdiau S, Le Toumelin P, Ait Kaci F, Riou B, Cupa M, et al. Assessing
residual neuromuscular blockade using acceleromyography can be deceptive in postoperative
awake patients. Anesth Analg. 2004;98:854–7.
27.
Miskovic A, Lumb AB. Postoperative pulmonary complications. Br J Anaesth. 2017;118:317–34.